Klaria AB and Purdue Pharma (Canada) announced they have entered into an exclusive development agreement for KL-01401 (Epinephrine Oromucosal Film). KL-01401 is a developmental stage formulation of epinephrine for emergency treatment of severe anaphylactic reactions in patients who are at increased risk for anaphylaxis. KL-01401 will be co-developed by Klaria and Purdue Pharma (Canada). The development agreement includes exclusive global license and supply options for the independently associated Purdue/Napp/Mundipharma network of companies upon achievement of defined milestones. Under the terms of the agreement, the total value of all milestones achievable is $55.2 million. In addition, Klaria will receive mid-to-upper single digit royalties on net sales. Further terms of the agreements give Klaria exclusive manufacturing rights to supply the global market with KL-01401. In order to complete the agreement with Purdue, Klaria AB has also added epinephrine to its license agreement with Uppsalagruppen Medical AB. In the agreement between Klaria and Uppsalagruppen, Uppsalagruppen will receive a 4% royalty on Klaria's net income from sales of KL-01401. KL-01401 is based on Klaria's novel patented drug delivery platform, which provides several benefits to patients who may require emergency treatment, for anaphylactic reactions. It is planned as an easy to use, non-injectable self-administered treatment that allows patients and their caregivers to discreetly carry a life-saving emergency treatment medication with them at all times.